메뉴 건너뛰기




Volumn 9, Issue 4, 2010, Pages 963-975

Dual inhibition of Akt/Mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN;

EID: 77950788603     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0763     Document Type: Article
Times cited : (156)

References (38)
  • 1
    • 3242777803 scopus 로고    scopus 로고
    • Advances in biology of multiple myeloma: Clinical applications
    • DOI 10.1182/blood-2004-01-0037
    • Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-618 (Pubitemid 38970551)
    • (2004) Blood , vol.104 , Issue.3 , pp. 607-618
    • Hideshima, T.1    Bergsagel, P.L.2    Kuehl, W.M.3    Anderson, K.C.4
  • 2
    • 34547106018 scopus 로고    scopus 로고
    • Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
    • DOI 10.1038/nrc2189, PII NRC2189
    • Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-598 (Pubitemid 47106630)
    • (2007) Nature Reviews Cancer , vol.7 , Issue.8 , pp. 585-598
    • Hideshima, T.1    Mitsiades, C.2    Tonon, G.3    Richardson, P.G.4    Anderson, K.C.5
  • 3
    • 27244434182 scopus 로고    scopus 로고
    • Identification and validation of novel therapeutic targets for multiple myeloma
    • DOI 10.1200/JCO.2005.05.024
    • Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005;23:6345-6350 (Pubitemid 46218845)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.26 , pp. 6345-6350
    • Hideshima, T.1    Chauhan, D.2    Richardson, P.3    Anderson, K.C.4
  • 4
    • 77950810666 scopus 로고    scopus 로고
    • Akt as a therapeutic target in mutiple myeloma
    • abstract n S83
    • Hideshima T, Raje N. Akt as a therapeutic target in mutiple myeloma. Haematologica 2007;92 [suppl 2]:abstract n S83.
    • (2007) Haematologica , vol.92 , Issue.SUPPL. 2
    • Hideshima, T.1    Raje, N.2
  • 5
    • 75149167181 scopus 로고    scopus 로고
    • Future perspectives in the management of myeloma
    • abstract n S134
    • Anderson KC. Future Perspectives in the Management of Myeloma. Haematologica 2007;92 [suppl 2]:abstract n S134.
    • (2007) Haematologica , vol.92 , Issue.SUPPL. 2
    • Anderson, K.C.1
  • 6
    • 0035525792 scopus 로고    scopus 로고
    • The AKT kinase is activated in multiple myeloma tumor cells
    • Hsu J, Shi Y, Krajewski S, et al. The AKT kinase is activated In multiple myeloma tumor cells. Blood 2001;98:2853-2855
    • (2001) Blood , vol.98 , pp. 2853-2855
    • Hsu, J.1    Shi, Y.2    Krajewski, S.3
  • 7
    • 0037013205 scopus 로고    scopus 로고
    • S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6
    • DOI 10.1074/jbc.M200043200
    • Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to lnterleukin-6. J Biol Chem 2002;277:15712-15720 (Pubitemid 34967845)
    • (2002) Journal of Biological Chemistry , vol.277 , Issue.18 , pp. 15712-15720
    • Shi, Y.1    Hsu, J.-H.2    Hu, L.3    Gera, J.4    Lichtenstein, A.5
  • 9
    • 0038281345 scopus 로고    scopus 로고
    • Downstream effectors of oncogenic ras in multiple myeloma cells
    • DOI 10.1182/blood-2002-08-2640
    • Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras In multiple myeloma cells. Blood 2003;101:3126-3135 (Pubitemid 36858006)
    • (2003) Blood , vol.101 , Issue.8 , pp. 3126-3135
    • Hu, L.1    Shi, Y.2    Hsu, J.-H.3    Gera, J.4    Van Ness, B.5    Lichtenstein, A.6
  • 12
    • 33644516582 scopus 로고    scopus 로고
    • Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis
    • DOI 10.1158/0008-5472.CAN-05-2447
    • Yan H, Frost P, Shi Y, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 2006;66:2305-2313 (Pubitemid 43294944)
    • (2006) Cancer Research , vol.66 , Issue.4 , pp. 2305-2313
    • Yan, H.1    Frost, P.2    Shi, Y.3    Hoang, B.4    Sharma, S.5    Fisher, M.6    Gera, J.7    Lichtenstein, A.8
  • 13
    • 10244229652 scopus 로고    scopus 로고
    • In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model
    • Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004;104:4181-4187
    • (2004) Blood , vol.104 , pp. 4181-4187
    • Frost, P.1    Moatamed, F.2    Hoang, B.3
  • 14
    • 33746365457 scopus 로고    scopus 로고
    • The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo
    • [abstract 1496]
    • Mitsiades N, McMullan C, Poulaki V, et al. The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo. ASH Annual Meeting Abstracts 2004 November 16 [abstract 1496], Blood 2004;104:418.
    • (2004) ASH Annual Meeting Abstracts 2004 November 16 , vol.104 , pp. 418
    • Mitsiades, N.1    McMullan, C.2    Poulaki, V.3
  • 15
    • 33750072949 scopus 로고    scopus 로고
    • Houghton PJ. mTOR and cancer therapy
    • Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-6446
    • (2006) Oncogene , vol.25 , pp. 6436-6446
    • Easton, J.B.1
  • 16
    • 33746637660 scopus 로고    scopus 로고
    • Current development of mTOR inhibitors as anticancer agents
    • DOI 10.1038/nrd2062, PII NRD2062
    • Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-688 (Pubitemid 44151605)
    • (2006) Nature Reviews Drug Discovery , vol.5 , Issue.8 , pp. 671-688
    • Faivre, S.1    Kroemer, G.2    Raymond, E.3
  • 17
    • 34347220473 scopus 로고    scopus 로고
    • Defining the role of mTOR in cancer
    • Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
    • (2007) Cancer Cell , vol.12 , pp. 9-22
    • Guertin, D.A.1    Sabatini, D.M.2
  • 18
    • 33947538050 scopus 로고    scopus 로고
    • Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
    • DOI 10.1038/sj.onc.1209990, PII 1209990
    • Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1Rdependent mechanism. Oncogene 2007;26:1932-1940 (Pubitemid 46474636)
    • (2007) Oncogene , vol.26 , Issue.13 , pp. 1932-1940
    • Wan, X.1    Harkavy, B.2    Shen, N.3    Grohar, P.4    Helman, L.J.5
  • 19
    • 23844438209 scopus 로고    scopus 로고
    • Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
    • DOI 10.1158/0008-5472.CAN-05-0917
    • Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and elF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-7058 (Pubitemid 41161231)
    • (2005) Cancer Research , vol.65 , Issue.16 , pp. 7052-7058
    • Sun, S.-Y.1    Rosenberg, L.M.2    Wang, X.3    Zhou, Z.4    Yue, P.5    Fu, H.6    Khuri, F.R.7
  • 22
    • 28344456323 scopus 로고    scopus 로고
    • A phase study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors
    • (Meeting Abstracts)
    • Tabernero J, Rojo F, Burns H, et al. A phase study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2005:3007.
    • (2005) J Clin Oncol , pp. 3007
    • Tabernero, J.1    Rojo, F.2    Burns, H.3
  • 23
    • 77950842339 scopus 로고    scopus 로고
    • Toxicology and safety pharmacology of nanoparticle albumin-bound (nab) rapamycin (ABI-009)
    • Abst 5732
    • Trieu V, De J, Yang A, et al. Toxicology and safety pharmacology of nanoparticle albumin-bound (nab) rapamycin (ABI-009). Proc Am Assoc Cancer Res (AACR) 2008;49:Abst 5732.
    • (2008) Proc Am Assoc Cancer Res (AACR) , vol.49
    • Trieu, V.1    De, J.2    Yang, A.3
  • 24
    • 42649132499 scopus 로고    scopus 로고
    • Protein nanoparticles as drug carriers in clinical medicine
    • Hawkins MJ, Soon-Shiong P, Desal N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876-885
    • (2008) Adv Drug Deliv Rev , vol.60 , pp. 876-885
    • Hawkins, M.J.1    Soon-Shiong, P.2    Desal, N.3
  • 25
    • 27644534999 scopus 로고    scopus 로고
    • Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade
    • DOI 10.1158/1535-7163.MCT-05-0068
    • Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-1540 (Pubitemid 41556435)
    • (2005) Molecular Cancer Therapeutics , vol.4 , Issue.10 , pp. 1533-1540
    • Shi, Y.1    Yan, H.2    Frost, P.3    Gera, J.4    Lichtenstein, A.5
  • 26
    • 33646577479 scopus 로고    scopus 로고
    • Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
    • Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity In human multiple myeloma cells. Blood 2006;107:4053-4062
    • (2006) Blood , vol.107 , pp. 4053-4062
    • Hideshima, T.1    Catley, L.2    Yasui, H.3
  • 29
    • 33747620519 scopus 로고    scopus 로고
    • Systems biology and combination therapy in the quest for clinical efficacy
    • DOI 10.1038/nchembio817, PII NCHEMBIO817
    • Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006;2:458-466 (Pubitemid 44266307)
    • (2006) Nature Chemical Biology , vol.2 , Issue.9 , pp. 458-466
    • Fitzgerald, J.B.1    Schoeberl, B.2    Nielsen, U.B.3    Sorger, P.K.4
  • 30
    • 39149124146 scopus 로고    scopus 로고
    • Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for Parkinson's disease explained via in silico studies
    • Jagatha B, Mythri RB, Vali S, Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via In silico studies. Free Radio Biol Med 2008;44:907-917
    • (2008) Free Radio Biol Med , vol.44 , pp. 907-917
    • Jagatha, B.1    Mythri, R.B.2    Vali, S.3    Bharath, M.M.4
  • 31
    • 36249019785 scopus 로고    scopus 로고
    • Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: A dynamic model
    • DOI 10.1016/j.neuroscience.2007.08.028, PII S0306452207010135
    • Vali S, Mythri RB, Jagatha B, et al. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 2007;149:917-930 (Pubitemid 350130291)
    • (2007) Neuroscience , vol.149 , Issue.4 , pp. 917-930
    • Vali, S.1    Mythri, R.B.2    Jagatha, B.3    Padiadpu, J.4    Ramanujan, K.S.5    Andersen, J.K.6    Gorin, F.7    Bharath, M.M.S.8
  • 32
    • 0021118703 scopus 로고
    • Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
    • Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
    • (1984) Adv Enzyme Regul , vol.22 , pp. 27-55
    • Chou, T.C.1    Talalay, P.2
  • 33
    • 33747819801 scopus 로고    scopus 로고
    • MTOR and cancer: Insights into a complex relationship
    • Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-734
    • (2006) Nat Rev Cancer , vol.6 , pp. 729-734
    • Sabatini, D.M.1
  • 34
    • 33947495259 scopus 로고    scopus 로고
    • Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells
    • DOI 10.1038/sj.onc.1209992, PII 1209992
    • Iwamaru A, Kondo Y, Iwado E, et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy In malignant glioma cells. Oncogene 2007;26:1840-1851 (Pubitemid 46474638)
    • (2007) Oncogene , vol.26 , Issue.13 , pp. 1840-1851
    • Iwamaru, A.1    Kondo, Y.2    Iwado, E.3    Aoki, H.4    Fujiwara, K.5    Yokoyama, T.6    Mills, G.B.7    Kondo, S.8
  • 36
    • 77950795869 scopus 로고    scopus 로고
    • Nanoparticle albumin-bound (nab) rapamycin as an anticancer agent
    • April 1418 Los Angeles, California. Abstract 4719
    • De T, Trieu V, Yim Z, et al. Nanoparticle albumin-bound (nab) rapamycin as an anticancer agent. Presented at: 98th American Association for Cancer Research Annual Meeting 2007; April 1418, 2007; Los Angeles, California. Abstract 4719.
    • (2007) 98th American Association for Cancer Research Annual Meeting 2007
    • De Trieu V, T.1    Yim, Z.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.